Neu auf wallstreet:online?
Jetzt registrieren | Login
x
Benutzername:

Passwort:

Angemeldet bleiben
Passwort vergessen?

Immunogen nach oben ausgebrochen!!! STRONG BUY!!! (Seite 2)

eröffnet am 11.09.00 10:45:13 von
Börsenanalyst

neuester Beitrag 02.05.01 09:31:50 von
Börsenanalyst
Beiträge: 18
ID: 238.800
Aufrufe heute: 0
Gesamt: 682


Beitrag schreiben Ansicht: Normal
Avatar
nortcev
schrieb am 18.09.00 16:37:32
Beitrag Nr. 11 (1.860.267)
hi woodawork,

det is ja klasse, ick bin auch än berliner, zumindestens dort jeboren, wa.
ging mir genauso wie dir mit immunogen.
ich bin am freitag "raus" (ärger) und heute wieder "rein". das spiel habe ich schon ein paarmal gemacht.
hat sich aber unter dem strich nicht rentiert (im vergleich zu einem dauerhaften engagement).
wäre schon froh, sollte sich immunogen über 28$ halten.
aktuell setzen wohl die ersten gewinnmitnahmen ein. über 600.000 aktien in einer stunde. das ist viel, sogar sehr viel.
gute geschäfte wünscht dir

nortcev.
Avatar
woodawork
schrieb am 18.09.00 17:22:37
Beitrag Nr. 12 (1.860.697)
hi nortcev!

10,000 shares were offered at 28 15/16 and taken in a heartbeat ...any size is grabbed

Die amis sind absolut bullish, und wir?

Wir Zittern!
Avatar
woodawork
schrieb am 20.09.00 12:24:28
Beitrag Nr. 13 (1.876.736)
keiner hier?
Seid ihr nur da, wenn`s supersteil nach Norden geht?
Avatar
woodawork
schrieb am 20.09.00 16:51:54
Beitrag Nr. 14 (1.879.808)
IMGN - Artikel im "Wall Street Journal"

Heard in New England: ImmunoGen`s Stream of
Partners May Keep Its Investors Dancing
----
By Andrew Caffrey

ImmunoGen looks like one of those overnight successes 20
years in the making
The stock of the small Cambridge, Mass., biotech company
rocketed to $25 from just $10 in July on the strength of
recent development deals with big biotech names
Genentech and Abgenix.
With such a move by the shares, potential investors may
feel as though they`ve missed out on the party. But fans
argue ImmunoGen has only started to show its potential,
and they predict a wave of more deals that could push the
company into the same league as biotech companies with
multibillion-dollar valuations.
"This is just the beginning," says James McCamant,
editor-at-large of Medical Technology Stock Letter in
Berkeley, Calif. The stock, he says, "has a long way to go."
Started in 1981, ImmunoGen has long labored to develop
technology that increases the potency of cancer-killing
drugs that are delivered via monoclonal antibodies to tumor
cells. Antibodies are typically synthesized proteins that have
a specific affinity for molecules found on the surface of cells
called antigens. Identify the antigens that are associated
with certain cancers, and you may be able to design an
antibody with toxic properties that seeks out tumors like a
guided missile.
But now scientists are discovering that some antibodies
may not be powerful enough in their own right to kill the
tumor, and need medicines attached to them like an extra
toxic warhead.
Several prior efforts by ImmunoGen to find the right mix of
antibodies and toxic agents failed, but in animal studies the
company`s latest version has shown powerful promise of
killing cancerous tumors outright. ImmunoGen`s particular
strength is in using a family of therapeutic agents that is
significantly more potent than other agents, and attaching
them to antibodies in such a way that they don`t damage
healthy cells on their way to hitting the cancer targets. If a
toxic agent attached to an antibody were to peel off into the
patient`s bloodstream while en route to the target tumors, it
could cause collateral damage to healthy cells.
The Genentech deals have put ImmunoGen in the spotlight.
Genentech, based in South San Francisco, already has an
antibody approved as a commercial drug, Herceptin, to
target breast cancer. Analysts say Genentech has
effectively conceded its very promising drug could be
improved with ImmunoGen`s technology, and in May signed
a deal that could be worth $40 million in payments to
Immunogen for achieving certain milestones -- such as
moving the product through clinical trials -- plus royalties on
sales of any drug that comes out of the partnership.
Given Genentech`s stature as a leading biotech company,
the deal was a "huge validation" for ImmunoGen, says Mr.
McCamant. "It means we can accept the idea that this is
really proven and important technology."
A short time later in May Genentech signed a second deal
with ImmunoGen to develop a larger number of modified
antibodies against a broader array of targets. Like the first
deal, ImmunoGen would get as much as $40 million in
milestone payments, plus royalties from sales of drugs
developed from its technology.
The Genentech agreements were followed by a 10-year
collaboration announced earlier this month with Abgenix,
another leading biotech company using monoclonal
antibodies. Though the terms weren`t disclosed, they are
believed to be similar to the Genentech venture terms.

The agreement with Abgenix is significant because the
Fremont, Calif., biotech concern has numerous ventures with
prominent genomics companies to use gene-mapping
technology to identify new antigens on cancerous cells.
Those antigens could in turn become targets for new drugs
that are equipped with ImmunoGen`s warheads. The more
targets Abgenix shoots at with ImmunoGen`s technology,
the more ImmunoGen gets paid.

Gary Hatton, of Granaham Investment Management,
Waltham, Mass., who invests in health-care stocks for
mutual fund giant Vanguard, is betting the Abgenix and
Genentech working partnerships will set off a chain reaction
among other companies trying to design monoclonal
antibodies for cancer therapy. If those two leaders in the field
have decided ImmunoGen`s technology is necessary,
"everybody`s going to want to use it," Mr. Hatton says.
"They are likely to do deal after deal." He recently bought
about 750,000 shares, or 2.3% of shares outstanding.

ImmunoGen`s chief executive, Mitchel Sayare, says he
hopes to unveil yet another deal before the end of the year,
and predicts many more to follow in the months and years
ahead. "When we model what the future looks like, it`s pretty
rosy in terms of cash flow," he says.

Indeed, William Tanner, an analyst at SG Cowen in Boston
who recently initiated coverage of ImmunGen with a "strong
buy," predicts ImmunoGen`s next partner will be a
genomics-based biotech firm.

Genomics is among the hottest, most highly valued sector
of the stock market right now, as investors are making huge
bets on companies that are decoding the human-gene
sequence or using that information to better understand the
nature of diseases and their possible cures.

"You might see" ImmunoGen "go straight for the throat with
a deal with a genomics company," says Mr. Tanner. "That`s
going to be a very big deal for the stock if that happens."

Messrs. Tanner and Hatton say there`s no reason
ImmunoGen`s stock couldn`t replicate the run of Abgenix, for
example. That stock once traded below $15 late last year,
and shot up quickly to near $30. But investors who bought
Abgenix at even that appreciated price have since been
rewarded, as the stock has climbed to near $80. Mr. Hatton
adds that once ImmunoGen`s market cap reaches $1 billion,
institutional investors that can`t own smaller stocks may
begin buying it, providing another boost.

The genomics frontier is particularly significant for
ImmunoGen because companies involved in this
gene-mapping science could conceivably identify any
number of potential markers in cancerous cells that could
serve as targets for ImmunoGen`s warheads.

"We do not know the limit" of antigen targets that could lead
to antibody therapies, says Dr. Sayare. "We`re just
beginning to get a taste of it because we`ve been contacted
by companies who say, `Hey, we have targets here. What
do we do?`"

This being biotech, there are still great risks. The early data
notwithstanding, the drugs developed with ImmunoGen`s
technology could turn out to be ineffective, and ImmunoGen
won`t be cashing in.

What`s more, biotech companies may be able to produce
antibodies that are powerful enough in their own right that
they wouldn`t need the additional arsenal provided by
ImmunoGen.

But analysts such as Mr. McCamant of the Medical
Technology Stock Letter predict there will be enough need to
modify antibodies that ImmunoGen will have plenty of
business in the years ahead.

"If this works as some of us believe," says Mr. McCamant,
"there`s a lot of upside ahead."
Avatar
woodawork
schrieb am 21.09.00 04:01:06
Beitrag Nr. 15 (1.885.164)
Das ist wohl mein Privat-Thread?
Gestern nach Kosolidierung Reversal! 29,50$!!
Wenn die 30$ geknackt sind gibts nur eins: anschnallen!
Zaghafte Prognose:
http://www.ragingbull.altavista.com/mboard/boards.cgi?board=IMGN&read=24524
Avatar
woodawork
schrieb am 21.09.00 04:35:02
Beitrag Nr. 16 (1.885.171)
Das ist wohl mein Privat-Thread?
Gestern nach Kosolidierung Reversal! 29,50$!!
Wenn die 30$ geknackt sind gibts nur eins: anschnallen!
Zaghafte Prognose:
http://www.ragingbull.altavista.com/mboard/boards.cgi?board=IMGN&read=24524
Avatar
KlngPong
schrieb am 02.05.01 00:39:58
Beitrag Nr. 17 (3.429.042)
Ein Analyst. Schaut mal auf das "Lebenswerk" Er berät Banken nach eigener Aussage.

Parkbanken?

:laugh: :laugh: :laugh: :laugh:
Avatar
Börsenanalyst
schrieb am 02.05.01 09:31:50
Beitrag Nr. 18 (3.429.679)
@Klng Pong

Schau Dir mal den Kursverlauf an!!!



Diejenigen, die auf mich gehört haben und mit Stoppkursen arbeiten,
konnten mit IMGN 100% Gewinn einfahren.

Du bist doch nur neidisch!!! :D

Börsenanalyst, der über solche Kasper nur lachen kann.

P.S. Wenn man sich schon Klng Pong nennt. Das sagt ja wohl alles. :laugh:




Beitrag zu dieser Diskussion schreiben

Investoren, die diesen Wert beobachten, informieren sich auch über:

WertpapierPerf. in %
-2,02
+4,06
-0,05
-1,28
+1,27
-0,47
-1,36
+0,10
-4,98
-4,00